Cuprina Holdings (Cayman) Limited is a biomedical and biotechnology company, which is engaged in the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. Its segments include Maggot Debridement Therapy Product (MDT) and Cosmeceutical Product. It manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as MDT, which is an effective alternative to surgical debridement. It has two lines of chronic wound care products in its pipeline, such as Collagen dressings, including sponges, particles and hydrogels utilizing bullfrog collagen derived from the valorization of abattoir waste streams of American bullfrogs (Lithobates catesbeianus) and products utilizing medical leeches for wound treatment.
公司代碼CUPR
公司名稱Cuprina Holdings (Cayman) Ltd
上市日期Apr 10, 2025
CEOMr. Yong Qi (David) Quek
員工數量14
證券類型Ordinary Share
年結日Apr 10
公司地址Block 1090
城市
上市交易所NASDAQ Capital Market Consolidated
國家Singapore
郵編169201
電話6585127275
網址https://cuprina.com/
公司代碼CUPR
上市日期Apr 10, 2025
CEOMr. Yong Qi (David) Quek